Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET
 
 
 
 

Glaxo in Hostile Bid for Human Genome Sciences

The battle for Human Genome Sciences (NASDAQ:HGSI) has become aggressive.

Last month, GlaxoSmithKline (NYSE:GSK) made a friendly bid for its long-time research partner, HGS. That offer was rebuffed.

Now, GSK says it wil make a hostile bid for the bio-tech company this week.

The takeover offer values HGS at $13 a share, roughly $2.6 billion, the Los Angeles Times reports. HGS has said that amount undervalues the company.

But GSK doesn’t plan to sweeten the offer. In a statement, the company said HGS has been given a “reasonable amount of time” to solicit other offers and that its shareholders should now decide whether the current offer is worthy.

Shares of HGS slipped slightly to around $14.50 in Wednesday trading, while GSK shares dipped 1% to around $45.60.


Article printed from InvestorPlace Media, https://investorplace.com/2012/05/glaxo-in-hostile-bid-for-human-genome-sciences/.

©2021 InvestorPlace Media, LLC